Abstract:Abstract Real-world evidence (RWE), the understanding of treatment effectiveness in clinical practice generated from longitudinal patient-level data from the routine operation of the healthcare system, is thought to complement evidence on the efficacy of medications from randomized controlled trials (RCTs). RWE studies follow a structured approach. (1) A design layer decides on the study design, which is driven by the study question and refined by a medically informed target population, patient-informed outcomes, and biologically informed effect windows. Imagining the randomized trial we would ideally perform before designing an RWE study in its likeness reduces bias; the new-user active comparator cohort design has proven useful in many RWE studies of diabetes treatments. (2) A measurement layer transforms the longitudinal patient-level data stream into variables that identify the study population, the pre-exposure patient characteristics, the treatment, and the treatment-emergent outcomes. Working with secondary data increases the measurement complexity compared to primary data collection that we find in most RCTs. (3) An analysis layer focuses on the causal treatment effect estimation. Propensity score analyses have gained in popularity to minimize confounding in healthcare database analyses. Well-understood investigator errors, like immortal time bias, adjustment for causal intermediates, or reverse causation, should be avoided. To increase reproducibility of RWE findings, studies require full implementation transparency. This article integrates state-of-the-art knowledge on how to conduct and review RWE studies on diabetes treatments to maximize study validity and ultimately increased confidence in RWE-based decision making.

The Time Has Come for “Real-World Studies” (RWS)

Real-world Evidence and Randomized Controlled Trials: the Initiation, Implementation, Progress Interpretation and Revelation of RCT DUPLICATE (part 2)

Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records

Utilization of real-world evidence in clinical research of medical devices

Real-World Evidence: A Primer

Discussion of solutions to ethical issues in real-world study

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective

The Use of Real-World Data/evidence in Regulatory Submissions.

On the use of RWD in support of regulatory submission in drug development

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

Observational studies to emulate randomized trials: Some real‐world barriers

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments

Examining the Use of Real‐World Evidence in the Regulatory Process

Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes.

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Real-World Evidence Gathering in Oncology: The Need for a Biomedical Big Data Insight-Providing Federated Network

An overview of Real-World Data infrastructure for cancer research

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14